Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
The study evaluates the rate beta-cell function decline in newly diagnosed type 2 diabetic
 patients on two different treatment regimens: insulin and metformin versus glyburide,
 metformin and pioglitazone.
This is a 72 months long randomized clinical trial longitudinally evaluating beta-cell
 function, as well as glycemic control and inflammatory markers in newly diagnosed type 2
 diabetic patients on two different treatment regimens: insulin and metformin versus
 glyburide, metformin and pioglitazone.
Inclusion Criteria:

 -  type 2 diabetes mellitus diagnosed within the prior 2 months

 -  HbA1c > 7% at the time of inclusion

 -  willing to perform intensive diabetes management

 -  able to comply with treatment and follow-up regimen

 Exclusion Criteria:

 -  HbA1c > 8% at time of randomization

 -  creatinine > 1.5 mg/dl

 -  liver function tests > 3 times the upper limit of normal

 -  severe anemia

 -  severe proliferative retinopathy

 -  NYHA class III or IV heart failure

 -  active CAD or recent (within 6 months) MI

 -  pregnant, willing to get pregnant, or not willing to practice any contraceptive method

 -  non-english speaking

 -  active heavy alcohol or illicit drug users (within past 6 months)

 -  history of lactic acidosis